Filing Details

Accession Number:
0001562180-24-000414
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-10 16:53:57
Reporting Period:
2024-01-08
Accepted Time:
2024-01-10 16:53:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1314102 Eyepoint Pharmaceuticals Inc. EYPT Laboratory Analytical Instruments (3826) 262774444
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1574261 A. Dario Paggiarino C/O Eyepoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown MA 02472
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-08 22,913 $3.26 59,418 No 4 M Direct
Common Stock Disposition 2024-01-08 22,913 $21.13 36,505 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-01-08 22,913 $0.00 22,913 $3.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
68,742 2033-01-05 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $21.94. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.